Ebola virus disease treatment research

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test

Retrieved on: 
Tuesday, August 1, 2023

The first patent application recently allowed relates to COVID and other neutralizing antibody (Nab) testing and treatment.

Key Points: 
  • The first patent application recently allowed relates to COVID and other neutralizing antibody (Nab) testing and treatment.
  • The allowance confirms that AXIM was a pioneer in developing a rapid point of care Nab test and its novelty.
  • Additionally, the company was notified by the USPTO of a second patent allowance for systems and methods for rapid diagnostic for various cancers.
  • 1 Utility Patent Application
    The invention relates to a Rapid Point of Care test for Human Monomeric Lacritin.

FlexAgain Launches Innovative New Joint Supplement To The US Market

Retrieved on: 
Wednesday, September 21, 2022

MIAMI, Sept. 21, 2022 /PRNewswire/ -- FlexAgain , established in the United Kingdom, is bringing their joint supplement formula to the US.

Key Points: 
  • MIAMI, Sept. 21, 2022 /PRNewswire/ -- FlexAgain , established in the United Kingdom, is bringing their joint supplement formula to the US.
  • The first batch of their joint supplement produced in the US sold out in weeks with FlexAgain now being on back order till November the 1st.
  • He continued, "Like most supplements, it's not a perfect solution, but it will definitely help more than anything else I've seen on the over-the-counter joint supplement market."
  • The supplement isn't designed to eradicate more severe cases of joint pain, but thousands of customers are now claiming that it has substantially reduced joint soreness and stiffness.

New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM▼ (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis

Retrieved on: 
Wednesday, October 13, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from a new subgroup analysis of the pivotal Phase 3 OPTIMUM trial.

Key Points: 
  • The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from a new subgroup analysis of the pivotal Phase 3 OPTIMUM trial.
  • Ponesimod demonstrated increased clinical benefit over teriflunomide in early disease subgroup compared with overall population.
  • Ponesimod demonstrated increased clinical benefit over teriflunomide in early disease subgroup compared with overall population.
  • Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a Randomized clinical trial.

CUNY SPH and the NYC Health Department to study long-acting antiretroviral therapy for HIV

Retrieved on: 
Monday, August 23, 2021

NEW YORK, Aug. 23, 2021 /PRNewswire/ -- The National Institute of Mental Health (NIMH) has awarded the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) and the New York City Department of Health and Mental Hygiene (NYC Health Department) a thirty-month grant to support long-acting injectable antiretroviral therapy access, uptake, and adherence among people with HIV enrolled in the Ryan White HIV/AIDS Program (hereafter "Ryan White").

Key Points: 
  • NEW YORK, Aug. 23, 2021 /PRNewswire/ -- The National Institute of Mental Health (NIMH) has awarded the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) and the New York City Department of Health and Mental Hygiene (NYC Health Department) a thirty-month grant to support long-acting injectable antiretroviral therapy access, uptake, and adherence among people with HIV enrolled in the Ryan White HIV/AIDS Program (hereafter "Ryan White").
  • This project aligns with the "Treatment" pillar from the U.S. Department of Health and Human Services Ending the HIV Epidemic (EHE) initiative and with two of the National Institutes of Health's priorities: reducing health disparities and implementation research on new HIV treatments.
  • Although HIV treatment advances have improved health and survival for people living with HIV in New York, racial/ethnic, age-related, geographic, and other disparities in viral suppression remain.
  • "But it is critically important to find out quickly, to optimize the public health impact of these advances."

CUNY SPH and NYC Health Department awarded $3.3 million to study new HIV intervention

Retrieved on: 
Wednesday, August 18, 2021

NEW YORK, Aug. 18, 2021 /PRNewswire/ -- The National Institute of Mental Health (NIMH) has awarded the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) and the New York City Department of Health and Mental Hygiene (NYC Health Department) a five-year, $3.3 million grant to test a new strategy to help people living with HIV achieve viral suppression.

Key Points: 
  • NEW YORK, Aug. 18, 2021 /PRNewswire/ -- The National Institute of Mental Health (NIMH) has awarded the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) and the New York City Department of Health and Mental Hygiene (NYC Health Department) a five-year, $3.3 million grant to test a new strategy to help people living with HIV achieve viral suppression.
  • Some existing HIV care continuum strategies, such as "data-to-care," target linkage to care and limit data sharing to medical providers.
  • Furthermore, since 2017, New York State regulations now permit person-level HIV surveillance data sharing with entities engaged in care coordination with primary care providers.
  • It will also use discrete choice experiments (DCEs) with service providers to assess their preferences for intervention delivery and specific intervention features.

Oyagen, Inc. Publishes Study On Its OYA1 As A "Highly Effective" Experimental Drug Candidate For Treating Infections By The Ebola Virus

Retrieved on: 
Thursday, January 7, 2021

This Study identified OYA1 as a "highly effective" antiviral against several viruses including Ebola and Lassa viruses.

Key Points: 
  • This Study identified OYA1 as a "highly effective" antiviral against several viruses including Ebola and Lassa viruses.
  • The published study results showed that OYA1 was "highly effective" in reducing the spread of Ebola Virus infection in laboratory tests with the live Ebola virus carried out by NIAID.
  • OYA1 proved equally effective in stopping Ebola infectivity when it was added at the time of infection or 24 hours after an infection.
  • OYA1 was abandoned as a drug candidate for cancer because it had no effect in reducing tumor burden.

Ridgeback Biotherapeutics LP Announces Priority Review of Biologics License Application for ansuvimab Ebola Treatment

Retrieved on: 
Wednesday, July 29, 2020

Ridgeback Biotherapeutics LP (Ridgeback), a biotechnology company experienced in antiviral drug development, today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted priority review designation for Ridgebacks investigational Ebola treatment, ansuvimab (mAb114).

Key Points: 
  • Ridgeback Biotherapeutics LP (Ridgeback), a biotechnology company experienced in antiviral drug development, today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted priority review designation for Ridgebacks investigational Ebola treatment, ansuvimab (mAb114).
  • The FDA granted Breakthrough Therapy Designation status to ansuvimab as a treatment for Ebola in September 2019.
  • This powerful experimental treatment has demonstrated an impressive survival benefit in Ebola patients and will supply much needed help to the patients and communities who battle Ebola.
  • Ridgeback has two late-stage treatments in development ansuvimab for the treatment of Ebola virus disease and EIDD-2801/MK 4482 for treatment of COVID-19.

Statement from FDA Commissioner Scott Gottlieb, M.D., on federal preparedness and FDA's response efforts to the Ebola virus outbreak in the Democratic Republic of Congo

Retrieved on: 
Wednesday, May 30, 2018

During the 2014-2015 Ebola outbreak, the FDA took new steps to advance the availability of investigational medical countermeasures, including drugs, vaccines and diagnostic tests.

Key Points: 
  • During the 2014-2015 Ebola outbreak, the FDA took new steps to advance the availability of investigational medical countermeasures, including drugs, vaccines and diagnostic tests.
  • As we closely monitor the current Ebola outbreak in the Democratic Republic of Congo (DRC), our team is employing our experiences, resources and knowledge from the 2014-2015 incidents.
  • We're committed to helping the people of the DRC effectively confront and end the current outbreak.
  • The FDA is focused on advancing the availability of an Ebola vaccine to help address the ongoing public health response.